Independent analysis of these results is probably a move by the company, directed related to the so called creditability issue, following release of the initial weight pill trial results in late 2004.
Slightly unusual move I think.....as they are the experts and could best access the results. Anyway why would you outsource to a third party to provide "bad" news.....when the company could just as easly do that themselves. You would only use an independent and neutral party to enhance authenticity and believability in the eyes of the market, on positive news.
Having said that......today they have downplayed a little, the ability of the trial to provide any indications of efficacy. Rather Dr Scollay just says its a trial to test safety and tolerability. (thats true-but these patients have sciatic pain.)
They have already done safey and tolerability with non-pain participants.....in a Phase 1 extension trial, in fact using using higher doses than those of this trial.
Probably just a neutral report for me.
But the big, overrider with this stock is its small market cap.......and the red hot drug area they are working in.
The drug has always been dose dependant......now as a result of that Phase 1 trail, an increased dosage in future can be used.
Following release of these mid-August results......investors need to weight up for themselves-
- is this product going to entice a big pharma to get involved with MBP ?.
Such a deal would mean MBP would have much more cash than their market capitalisation. Just some hint of efficany this time........would move the shareprice. A big pharma deal would be there to be had by MBP........and with the option of higher doses. (Share price 55 cents)
Todays report was neutral (my view)....but am very condfident here in which directon we will see the shareprice move.
Add to My Watchlist
What is My Watchlist?